MabThera
| Name | MabThera |
|---|---|
| Active Substance | rituximab |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| ATC Code | L01XC02 |
| Medicinal product marketed in the Croatia | Da |
| Educational materials for healthcare professionals |
Vodič o izgledu, čuvanju, rukovanju i primjeni, verzija 2 Kartica usporedbe supkutane i intravenske primjene, verzija 2 Knjižica za zdravstvene radnike, verzija 6 |
| Educational materials for patients / caregivers |
Priručnik za bolesnike, verzija 5 Kartica za bolesnike |
Note
The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera
The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm
